Parikh Anand Kiran 4

What Happened Anand Kiran Parikh, President, CEO and Director of Faeth Therapeutics, was granted a performance-based stock option covering 398,018 shares on July 21, 2026. The award shows an acquisition price of $0.00 (derivative grant), so no cash was paid. The option only becomes exercisable if specified performance and service conditions are met.

Key Details

• Transaction date: July 21, 2026; Form 4 filed July 23, 2026 (appears timely under Form 4 rules).
• Grant: 398,018-share performance-based option; reported acquisition price $0.00; reported value $0 at grant.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote F1 (performance vesting): Option vests only after the later of (a) any 30-consecutive-calendar-day average closing price ≥ $70.00 and (b) the first anniversary of grant; if the $70 hurdle is not met by the fourth anniversary, the option is forfeited. Continued service is required for vesting.
• Footnote F2 (change in control): If a Change in Control occurs before the performance period ends and the per-share consideration is ≥ $70 (subject to adjustment), the hurdle is deemed met and the option vests in full immediately prior to the transaction, subject to continued service; otherwise it is forfeited.

Context This filing reports a compensation grant (derivative award), not a market purchase or sale. Performance-based options like this are common executive compensation tied to a specific stock-price target; they do not indicate an immediate cash outlay or an insider sale.